-transparent.png){kind=logo}
In a 6-year period, 435 alleged cannabis samples were accessioned by an urban street drug analysis program, and clinical histories were correlated with laboratory results. The most common reason for submission of a sample was suspicion of adulteration; however, such samples were usually unadulterated but had high potency as measured by delta 9-tetrahydrocannabinol concentration. Adverse reactions occurring in nonadulterated samples were not associated with high potencies. The validity of cannabis products distributed illicitly and analyzed was over 94%. Exotic varieties were more potent than less expensive cannabis. The absolute amount of delta 9-tetrahydrocannabinol ranged from 1.5 to 144.9 mg.
R S Ritzlin, and
R C Gupta, and
G D Lundberg
May 1997,
Annals of internal medicine,
R S Ritzlin, and
R C Gupta, and
G D Lundberg
August 1984,
Clinical pharmacology and therapeutics,
R S Ritzlin, and
R C Gupta, and
G D Lundberg
January 1989,
Psychopharmacology,
R S Ritzlin, and
R C Gupta, and
G D Lundberg
August 1967,
Journal of the American Chemical Society,
R S Ritzlin, and
R C Gupta, and
G D Lundberg
January 1987,
Journal of analytical toxicology,
R S Ritzlin, and
R C Gupta, and
G D Lundberg
December 2002,
Psychopharmacology,
R S Ritzlin, and
R C Gupta, and
G D Lundberg
January 1978,
Forensic science,
R S Ritzlin, and
R C Gupta, and
G D Lundberg
January 1976,
Annals of the New York Academy of Sciences,
R S Ritzlin, and
R C Gupta, and
G D Lundberg
January 1988,
Journal of psychoactive drugs,
R S Ritzlin, and
R C Gupta, and
G D Lundberg
January 1975,
L'Encephale,
